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Background: Planned induction of labor for various indications has become an established part of modern Obstetric practice. 
While the efficacy of misoprostol, a prostaglandin E1 analog as a cervical ripening labor induction agent has been established, 
the appropriate route and dosage are still objected to ongoing research.
Objective: This study aims at comparing the efficacy of vaginally administered with sublingual misoprostol for cervical 
ripening and labor induction.
Methodology: One hundred (100) pregnant women at term who fulfill the inclusion criteria were equally randomized into the 
two arms of the study to receive either 25 µg of misoprostol sublingually or 25µg vaginally. The induction delivery interval 
and fetal outcomes were compared in the two arms of the study.
Results: The vaginal group required more doses of misoprostol than the sublingual group (1.68 ± 0.74 versus 1.26 ± 0.44, 
P = 0.005). Time from the administration of the first dose of misoprostol to the achievement of a Bishop score of 7 or active 
phase labor was shorter in the sublingual group than the vaginal route group (5.04 ± 1.77 hours versus 6.32 ± 1.36 hours, 
P = 0.001). Induction‑delivery interval was shorter in the sublingual group than the vaginal route (10.02 ± 2.37 hours versus 
11.12 ± 3.97 hours) although the difference was not statistically significant (P = 0.098). The mean Apgar scores at 1 min 
and 5 min were slightly better in the vaginal group than the sublingual group but the difference did not assume statistical 
significance (Apgar scores at 1 minute: 7.62 ± 0.83 versus 7.72 ± 0.88, at 5 minutes: 8.94 ± 1.23 versus 9.22 ± 0.46 for the 
sublingual versus the vaginal group, respectively, P = 0.561).
Conclusions: The two routes of sublingual and vaginal administration showed comparable safety and effectiveness for 
cervical ripening and induction of labor in low‑risk pregnancies at term. However, the sublingual route appears to be superior 
in terms of easy administration and patients’ satisfaction.
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Introduction
While the onset of labor is spontaneous in the majority 
of pregnant women at term, a few, however, require 
artificial initiation of labor for medical, Obstetric or social 
reasons.[1-4] Many methods have been described for cervical 
ripening and induction of labor, ranging from natural to 
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modern methods.[4,5] Mechanical methods include stripping 
or sweeping of the fetal membranes, use of hygroscopic 
dilators, and Foley’s catheter.[6-9] Pharmacological methods 
like the use of prostaglandins or their analogs have been 
well documented and tried.[4,5,9] In an attempt to meet the 
demand for successful induction of labor and vaginal delivery, 
cervical ripening is a necessary pre-requisite.[10] The use of 
pharmacological agents particularly the prostaglandins or 
their analogs appear predominant in cervical ripening and 
induction of labor in many centers in modern Obstetric 
practice.[11]
Misoprostol was first manufactured for prophylaxis and 
treatment of gastric and duodenal ulcers caused by 
non-steroidal anti-inflammatory drugs.[12] Its uterotonic 
effect has propelled many studies that demonstrated its use 
in cervical ripening and induction of labor.[13-15] However, 
the ideal dose and dosing interval to be used for obstetric 
indications as well as different routes of administration 
have been the subject of different studies.[13,16-18] This study 
was designed to compare two routes of administration of 
misoprostol, viz. sublingual and transvaginal routes.
Materials and Methods
The study was a prospective randomized study of healthy 
pregnant women, with a singleton pregnancy who registered 
for antenatal care and delivery during the study period. 
Approval for the study was obtained from the Ethics Review 
Committee of the Hospital. The approval was obtained on 
25-06-2014. The inclusion criteria included: valid indication 
for	 induction	of	 labor,	 singleton	pregnancy	at	≥37	weeks	
gestational	age,	Bishop’s	score	of	≤5,	cephalic	presentation,	
and normal fetal heart rate. The patients with the following 
conditions were excluded: malpresentation, unexplained 
vaginal bleeding, multiple gestations, placenta praevia, 
estimated fetal weight of >4000 gm, abnormal fetal heart 
rate, evidence of cephalopelvic disproportion, known allergy 
to prostaglandins, any pre-existing medical illness such as 
renal disease, cardiac disease, hepatic dysfunction, and 
clotting disorders, any known contraindication to receiving 
prostaglandins like asthma, glaucoma. Others are active 
genital infection, suspected chorioamnionitis, previous 
cesarean delivery or uterine surgery, grand multiparty, 
nonconsenting patients, and severe preeclampsia/eclampsia. 
The calculated minimum sample size to achieve a statistical 
power of 80% and 5% significant level was 40. A deliberate 
oversampling of 25% was allowed for nonresponders/
dropouts. This gave a total of 50 parturient on each arm 
of the study. All patients were adequately counseled and 
their informed consent obtained before their inclusion 
in the study. The antenatal records were reviewed for 
co-existing medical conditions and the history of the index 
pregnancy. Thereafter, the first-trimester ultrasound scan 
was reviewed when available to ascertain the estimated 
gestational age. History taking, physical examination, and 
investigations were used to determine the eligibility of 
unbooked patients. The patients were assigned using random 
numbers generated, using a table of random numbers to 
receive intravaginal 25 µg of misoprostol or 25µg sublingual 
misoprostol (Evan Pharmaceuticals, Nigeria). Group allocation 
was predetermined and placed in consecutively numbered 
and sealed opaque envelopes. All eligible patients who gave 
informed consent for study participation were assigned 
sequential study numbers. The primary investigator who was 
responsible for maintaining the envelopes was contacted and 
opened the corresponding numbered envelope for treatment 
allocation.
All consenting patients underwent clinical Obstetric 
examination to exclude the presence of any of the exclusion 
criteria immediately before commitment to the treatment 
allocation. Initial Bishop Scores were assessed by a senior 
resident doctor and were re-assessed by the same individual. 
Biophysical profile, ultrasonography, blood grouping and 
cross-matching, and packed cell volume were also performed.
All pregnant women who fulfilled the study criteria received 
misoprostol in the posterior fornix of the vagina or sublingually 
every 4 hours for a maximum total of 6 doses for cervical 
ripening or until labor is established, with the maximum 
exposure time to the agent being 24 hours. Repeat dose of 
misoprostol was not administered in patients who progressed 
to the active phase of labor or who had adequate uterine 
contractions or patients who developed complications. 
Oxytocin induction and active management of labor were 
commenced in those patients with satisfactory Bishop Score 
who did not develop spontaneous active labor after maximum 
exposure to misoprostol. Oxytocin infusion was not started 
until at least 4 hours after the last dose of misoprostol. By 
use of a standardized protocol, oxytocin infusion was used 
by gravity-assisted method commencing with 5 miu/min and 
increasing at intervals of 30 minutes to achieve adequate 
uterine contractions pattern, i.e. at least 3 strong uterine 
contractions in 10 minutes, each lasting 40-60 seconds. In the 
active phase of labor, routine intrapartum management was 
done. Fetal heart rate monitoring was done by intermittent 
auscultation with Pinnard’s fetal stethoscope (or when 
necessary sonic aid or cardiotocograph) at intervals of 
30 minutes. Evaluation of uterine contractile pattern for 
frequency, duration, and intensity of each contraction was 
done for 10 minutes at intervals of 30 minutes, while maternal 
vital signs—pulse rate was assessed every half hours, blood 
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pressure and temperature four hourly. These information 
were charted on partograph as recommended by the World 
Health Organization (WHO).
Abnormal parameters in labor were treated in accordance 
with the standard obstetric intervention (s) appropriate for 
each situation.
Data processing
Data entry was into a standard proforma and statistical 
analysis was performed with Chi-square (X2), Student t-test, 
Mann–Whitney U, and Fisher’s exact test when appropriate. 
All tests were two-tailed (or sided) with 0.05 level of 
significance. Differences in age and estimated gestational 
age were analyzed with Student t-test, while differences 
in gravidity, parity, route of delivery, and presence of 
complications were analyzed with X2 (chi square) and Apgar 
and Bishop’s Scores were analyzed by Mann–Whitney U test 
using statistical package of Statistical Package for the Social 
Sciences (SPSS) version 21.
Results
One hundred women were randomized into the study. 
Fifty (50) women were randomized to receive 25 µg 
misoprostol via the vaginal route while another 50 
received 25 µg misoprostol for cervical ripening via the 
sublingual route. The mean ages and other demographic 
characteristics were comparable, 29.4 ± 3.5 years and 
29.3 ± 3.9 years (P = 0.161) for sublingual and vaginal 
group, respectively.
Postdate pregnancy, mild preeclampsia, and premature 
rupture of membranes were the major indications for 
induction of labor, accounting for 39%, 26%, and 21%, 
respectively. Other indications were: suspected intrauterine 
growth restriction, chronic hypertension, and diabetes 
mellitus in pregnancy [Table 1]. These indications were 
comparable in both the sublingual and vaginal groups. 
The mean Bishop score prior to commencement of 
cervical ripening and induction of labor were (2.56 ± 0.95 
and (2.28 ± 0.88) for the vaginal and the sublingual arms, 
respectively (P = 0.328).
Figure 1 is a box plot illustrating the time required from 
cervical ripening to delivery in both groups. The difference 
in the time from onset of cervical ripening to delivery was 
not statistically significant in the two groups.
Table 2 compares the effectiveness of misoprostol in 
achieving cervical ripening and induction of labor when 
administered via the sublingual and vaginal route by 
comparing the time required to achieve uterine contractions, 
the time required to achieve Bishop score of greater than 7 
or active phase labor, and the need for augmentation in the 
two groups of participants. The difference in the duration 
of time from administration of misoprostol to the onset of 
uterine contractions was statistically significant between 
the two groups, the mean onset of uterine contraction 
was earlier (2.76 ± 1.71 hours) for the sublingual group 
than for the vaginal group (4.04 ± 2.32 hours) (Z -2.760, 
P value = 0.005). The total number of doses of misoprostol 
required for cervical ripening and induction of labor was 
more in the vaginal group than the sublingual group with 
the difference being statistically significant. Two patients 
in the vaginal arm required a maximum dosage of 100µg 
(4 doses). The mean of the number of doses of misoprostol 
in the sublingual group was 1.26 ± 0.44 while that of the 
vaginal group was 1.68 ± 0.74. (P value = 0.001). Time from 
the administration of misoprostol to achievement of a Bishop 
score of >7 or active phase labor was significantly shorter 
in the sublingual group (5.04 ± 1.77 hours) than the vaginal 
group (6.32 ± 1.36 hours) (P value = 0.001).
The need for augmentation of labor was more in the 
sublingual group (28%) than the vaginal group (14%) although 
Table 1: Indications for induction of labor
INDICATION Number n PERCENTAGE
Prolonged pregnancy 39 39
Pregnancy induced hypertension/Preeclampsia 26 26
Premature rupture of membrane (PROM) 21 21
Intrauterine growth restriction (IUGR) 8 8
Chronic hypertension 4 4
Diabetes 2 2
TOTAL 100 100
Figure 1: Box Plot showing the mean time from the start of cervical ripening 
to delivery (in hours) in both groups to be similar
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the difference was not statistically significant (Z = 2.954, 
P value = 0.140). The interval between commencement of 
cervical ripening and delivery was shorter in the sublingual 
group (mean 10.02 ± 2.37 hours) than the vaginal 
group (mean 11.12 ± 3.97 hours) although the difference 
was not statistically significant (P = 0.098).
The majority of patients were satisfied with the route of 
administration of misoprostol and outcome of labor in the 
two groups (84% sublingual and 78% in the vaginal group). 
Although the degree of satisfaction was more in favor of the 
sublingual route of administration there was no statistically 
significant difference in patient satisfaction in the two 
groups (P value 0.636). No patient was dissatisfied with the 
route of administration of misoprostol. Table 3 shows the 
labor outcomes and complications of labor in the sublingual 
and vaginal route. Majority of patients in both groups had 
vaginal delivery following cervical ripening and induction 
of labor (90% in the sublingual group and 94% in the vaginal 
group). Six (6%) patients in each group had cesarean delivery 
with no statistically significant difference in the route of 
delivery in both groups. In the study, 98% and 94% of patients 
in the sublingual and vaginal route, respectively did not have 
any complication in labor, while 2% and 6% had complications 
during labor following sublingual and vaginal administration 
of misoprostol, respectively. While 96% of patients in both 
groups did not have any maternal postpartum complications, 
4% had postpartum complications in each group. The route 
of delivery, complications during labor, and postpartum 
complications were similar in both groups of participants.
Table 4 shows the fetal outcomes in both groups of 
participants. The preinduction fetal heart rate was similar 
in both arms of the study prior to the administration 
of misoprostol for cervical ripening and induction of 
labor (sublingual 140.14 ± 7.18; and vaginal 142.78 ± 7.29, 






Time to onset of contractions (Hours) 2.76±1.71 4.04±2.32 ‑2.760 0.005†
Time from cervical ripening to Bishop score of 7 or active phase labour (Hours) 5.04±1.77 6.32±1.36 ‑3.205 0.001†
Cervical ripening to delivery Interval (Hours) 10.02±2.37 11.12±3.97 ‑1.673 0.098*
Total Number of Doses of Misoprostol used
1 dose only (25 ug) 37 (74.0) 22 (44.0) 10.292 0.005**
2 doses (50 ug) 13 (26.0) 24 (48.0)
3 doses (75 ug) 0 (0.0) 2 (4.0)
4 doses (100 ug) 0 (0.0) 2 (4.0)
Mean of the number of doses of Misoprostol (mean±SD) 1.26±0.44 1.68±0.74 ‑3.441 0.001*
Need for Augmentation
Yes 14 (28.0) 7 (14.0) 2.954 0.140**
No 36 (72.0) 43 (86.0)
Time from start to augmentation (Hours) 6.50±1.40 8.71±3.40 ‑2.140 0.046†
†Z ‑ Mann‑Whitney U test. *Independent t‑ test ** Chi‑square test
Table 3: Labour outcomes and complications of labour with the route of misoprostol
Sublingual group (n=50) Vaginal group (n=50) χ2 P
Route of delivery
Spontaneous Vaginal Delivery 45 (90.0) 47 (94.0) 1.754 0.598**
Instrumental Vaginal Delivery 2 (4.0) 0 (0.0)
Caesarean Delivery 3 (6.0) 3 (6.0)
Complications of Labour
No Complications 49 (98.0) 47 (94.0) 1.388 0.617**
Foetal Distress 1 (2.0) 2 (4.0)











No Complications 48 (96.0) 48 (96.0) 2.553 0.495**
Wound Infection 2 (4.0) 1 (2.0)
Puerperal Sepsis 0 (0.0) 1 (2.0)
**Fisher’s exact test
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P value = 0.071). Mean Apgar scores at 1 min and 5 min 
were better in the vaginal group than the sublingual group 
although the difference was not statistically significant 
(P value = 0.561); the mean Apgar score at 1 minute is 
7.62 ± 0.83 for the sublingual group and 7.72 ± 0.88 for the 
vaginal group. Mean Apgar score at 5 min was 8.94 ± 1.23 
for the sublingual group and 9.22 ± 0.46 for the vaginal 
group (P value = 0.561).
The mean birth weight of babies in both groups 
was similar, sublingual group 3.1 ± 0.31 kg, vaginal 
group 3.18 ± 0.41 kg, P value = 0.283. The need for special 
care baby unit admission was slightly more following 
sublingual administration of misoprostol (14%) than after 
vaginal administration (10%), although the difference was 
not statistically significant (P = 0.760).
Discussion
The result of this study further supports the effectiveness of 
misoprostol as an agent for cervical ripening and induction 
of labor with successful vaginal delivery achieved in 94% 
of parturient in each arm of the study in conformity with 
previous studies.[16,18-23] Cesarean delivery rate was the same 
in both groups (6%). This is similar to the study by Adeniyi 
et al.[16] in Ibadan where 92% had vaginal delivery in the 25 µg 
arm of the study and about 8% cesarean delivery. A study 
by Siwatch et al.[19], which also used 25 µg misoprostol 
for cervical ripening and induction showed 93% and 91% 
vaginal delivery following administration of misoprostol by 
the vaginal and sublingual route, respectively. Studies by 
El Mehdi Hissane et al.[21] in Morocco showed 75% and 73% 
vaginal delivery following sublingual and vaginal routes of 
administration, respectively.
Prolonged pregnancy was the commonest indication for 
induction in this study, accounting for 39% and others 
were preeclampsia (26%) and premature rupture of 
membranes (21%). Suspected intrauterine growth restriction, 
chronic hypertension, and diabetes accounted for the 
remaining 14%. In a similar study comparing two dosage forms 
of misoprostol for cervical ripening and induction of labor by 
Adeniyi et al.[16] in Ibadan Nigeria, prolonged pregnancy was 
also the most common indication, and accounted for about 
74% of the participants, unlike in the study by Siwatch et al. 
in India in which hypertensive disorders was the highest 
indication for induction (44%), while prolonged pregnancy 
accounted for 24%.[19]
The onset of uterine contractions was significantly faster 
in the sublingual group, 2.76 ± 1.71 hours than the 
vaginal group, 4.04 ± 2.32 hours (P = 0.005). Also, the 
mean number of doses of misoprostol in the sublingual 
group was smaller (1.26 ± 0.44) than that of the vaginal 
group (1.68 ± 0.74) (P = 0.005). These findings corroborate 
the pharmacokinetic studies by Zeiman et al.[20] which 
showed that the peak plasma concentration of misoprostol 
was reached in the shortest time and higher peak value in 
the sublingual group. This could possibly explain the faster 
onset of uterine contractions and the smaller mean number 
of doses of misoprostol observed in the sublingual group. 
This was in contrast to studies by Siwatch et al.[19] which 
showed that a higher mean number of doses of sublingual 
misoprostol 2.05 ± 0.980, than the vaginal dose 1.81 ± 0.843 
was required for cervical ripening and induction of labor. 
Studies by Caliskan et al. and Filho et al. also showed that 
the number of doses required for the sublingual route of 
misoprostol was more than the vaginal route of misoprostol 
administration.[21,22]
The need for augmentation of labor was more (28%) in the 
sublingual group than the vaginal group (14%), which was 
similar to the study by Siwatch et al.[19] in which 38.8% and 
28.8% required augmentation in the sublingual and vaginal 
routes respectively. There was however no statistically 
significant difference in the need for augmentation 
between the routes of administration in the Siwatch et al. 
study.[19] The less need for augmentation in the vaginal arm 
could be possibly explained by the local effect of vaginally 
administered misoprostol on the cervix which may contribute 
to its sustained action and hence less requirement for 
augmentation.[24-30] The neonatal outcomes in terms of birth 
weights, Apgar scores, the passage of meconium, admission 
to special care baby units, and indication for such admissions 
were comparable to other similar studies by Adeniyi et al.[16] 
and Siwatch et al.[19]
The pattern of patient satisfaction in both groups found 
in this study was similar to that previously demonstrated 
by Nassar A et al. [26] where sublingual misoprostol 
Table 4: Comparison of the Foetal outcomes







Pre‑induction FHR* 140.14±7.18 142.78±7.29 ‑1.824 0.071
APGAR Score
Apgar Score @ 1 Min 7.62±0.83 7.72±0.88 ‑0.584 0.561
Apgar Score @ 5 Mins 8.94±1.23 9.22±0.46
Birth Weight (Kg) 3.1±0.31 3.18±0.41 ‑1.078 0.283
SCBU Admission
Yes 7 (14.0) 5 (10.0) 0.379 0.760**
No 43 (86.0) 45 (90.0)
**Chi‑square test. *FHR=Foetal heart rate
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(50 micrograms) was associated with a significantly higher 
patient satisfaction rate compared with a similar dose of 
vaginal misoprostol because the sublingual administration 
offers additional choice to women, in particular those 
wishing to avoid vaginal administration. The outcome 
of this study is in support of previous studies that found 
misoprostol an effective cervical ripening agent.[31-36] The 
generally lowlabor complications observed in the study 
were similar to the findings from previous studies.[16,34] The 
low level of complications may be due to the strict protocol 
criteria of 4-hour dosing interval and not commencing 
oxytocin augmentation earlier than 4 hours after the last 
dose of misoprostol. Maternal postpartum complications 
identified in the 2 groups were similar and were most 
probably not directly related to misoprostol or its route 
of administration. There was no statistically significant 
difference in the postpartum complications in both groups.
Conclusions
The two routes of sublingual and vaginal administration of 
misoprostol showed comparable safety and effectiveness for 
cervical ripening and induction of labor low-risk pregnancies 
at term. Both routes of administration in this study were 
devoid of significant side effects and have comparably 
favorable fetal and maternal outcomes. Although the 
sublingual route appears more convenient for administration 
and reduces the frequency of digital vaginal examination.
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